Free Trial

Praxis Precision Medicines (PRAX) Earnings Date, Estimates & Call Transcripts

Praxis Precision Medicines logo
$45.94 -1.33 (-2.81%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$45.98 +0.05 (+0.10%)
As of 08/8/2025 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Praxis Precision Medicines Earnings Summary

Praxis Precision Medicines announced Q2 2025 & Study Result earnings on August 4, 2025, reporting an EPS of -$3.31, which topped analysts' consensus estimates of -$3.40 by $0.09. With a trailing EPS of -$12.29, Praxis Precision Medicines' earnings are expected to decrease next year, from ($10.22) to ($12.22) per share.

Latest Q2 2025 & Study Result
Earnings Date
Aug. 4Estimated
Consensus EPS
(Aug. 4)
-$3.40
Actual EPS
(Aug. 4)
-$3.31 Beat By $0.09

Q2 2025 & Study Result Earnings Resources

Get Praxis Precision Medicines Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Praxis Precision Medicines and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

PRAX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PRAX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Praxis Precision Medicines Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20252-$3.18-$2.14-$2.66
Q2 20252-$3.83-$2.94-$3.39
Q3 20252-$3.78-$3.23-$3.51
Q4 20252-$4.25-$3.24-$3.75
FY 2025 8 -$15.04 -$11.55 -$13.30
Q1 20262-$4.23-$2.00-$3.12
Q2 20262-$4.50-$2.04-$3.27
Q3 20262-$4.60-$2.08-$3.34
Q4 20262-$4.64-$2.13-$3.39

Praxis Precision Medicines Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025 & Study Result-$3.40-$3.31+$0.09-$3.31$0.15M-
5/2/2025Q1 2025-$3.20-$3.29 -$0.09-$3.29$0.20M-
2/28/2025Q4 2024-$2.76-$2.94 -$0.18-$2.94$0.36M$7.48M
11/6/2024Q3 2024-$2.01-$2.75 -$0.74-$2.75$0.53M$0.30M
8/13/2024Q2 2024-$2.38-$1.74+$0.64-$1.74$1.44M$0.36M
5/13/2024Q1 2024-$2.01-$2.84 -$0.83-$2.84$2.75M$0.43M
3/5/2024Q4 2023-$3.05-$2.97+$0.08-$2.97$0.30M$0.52M
11/7/2023Q3 2023-$5.25-$2.70+$2.55-$0.18-$0.47M
8/9/2023Q2 2023-$9.90-$7.35+$2.55-$0.49-$0.78M

Praxis Precision Medicines Earnings - Frequently Asked Questions

Praxis Precision Medicines (NASDAQ:PRAX) last announced its quarterly earning data on Monday, August 4, 2025. Learn more on PRAX's earnings history.

In the previous quarter, Praxis Precision Medicines (NASDAQ:PRAX) reported ($3.31) earnings per share (EPS) to beat the analysts' consensus estimate of ($3.40) by $0.09. Learn more on analysts' earnings estimate vs. PRAX's actual earnings.

The conference call for Praxis Precision Medicines' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Praxis Precision Medicines' latest earnings report can be read online.
Read Transcript

Praxis Precision Medicines (NASDAQ:PRAX) has a recorded annual revenue of $8.55 million.

Praxis Precision Medicines (NASDAQ:PRAX) has a recorded net income of -$182.82 million. PRAX has generated -$12.29 earnings per share over the last four quarters.

Praxis Precision Medicines' earnings are expected to decrease from ($10.22) per share to ($12.22) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:PRAX) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners